Related Experiment Videos
Beta 2-microglobulin predicts survival in primary systemic amyloidosis
M A Gertz1, R A Kyle, P R Greipp
1Dysproteinemia Clinic, Mayo Clinic, Rochester, Minnesota 55905.
The American Journal of Medicine
|November 1, 1990
Summary
Elevated beta 2-microglobulin (B2M) levels in primary systemic amyloidosis patients indicate significantly shorter survival. Routine B2M measurement can identify patients with poor prognosis, aiding treatment decisions.
Area of Science:
- Hematology
- Nephrology
- Oncology
Background:
- Primary systemic amyloidosis (PSA) is a rare plasma cell disorder.
- Prognostic markers are crucial for managing PSA patients without multiple myeloma.
Purpose of the Study:
- To evaluate if serum beta 2-microglobulin (B2M) levels predict survival in PSA.
- To determine B2M's utility as a prognostic factor in PSA.
Main Methods:
- Retrospective analysis of 131 untreated PSA patients without multiple myeloma.
- Median follow-up of 8 years with no loss to follow-up.
- Multivariate proportional-hazards modeling including congestive heart failure and B2M levels.
Main Results:
- Increased B2M levels correlated with significantly shorter median survival (10.8 vs. 32.9 months, p < 0.001).
- B2M remained a significant independent predictor of survival after adjusting for congestive heart failure.
- Elevated B2M was associated with nephrotic-range proteinuria (p = 0.05).
Conclusions:
- Serum B2M is a valuable prognostic biomarker in PSA.
- Routine B2M measurement can identify patients with unfavorable outcomes.
- B2M aids in risk stratification for primary systemic amyloidosis.